SUBSCRIBE
SUBSCRIBE

Indapta Therapeutics

IN THE PRESS
Press Releases
Indapta Therapeutics Secures $22.5 Million to Advance Clinical Trials of Innovative Cancer and Autoimmune Treatments
December 17, 2024
 · 
2 min read
Press Releases
Indapta Therapeutics Announces Clinical Study Collaboration With Sanofi on Multiple Myeloma Program
December 6, 2024
 · 
2 min read
Press Releases
Indapta Therapeutics Presents Clinical and Preclinical Data of Allogenic Natural Killer Cell Therapy at Society for Immunotherapy of Cancer Meeting
November 7, 2024
 · 
4 min read
BioForest
Indapta Therapeutics to Highlight its g-NK Cell Platform for the Treatment of Cancer and Autoimmune Disease in a Plenary Session at New York Academy of Sciences Frontiers in Cancer Immunotherapy Conference
May 23, 2024
 · 
3 min read
BioForest
Indapta Therapeutics Awarded $4.5 Million by CPRIT to Advance Clinical Development of its Allogenic Natural Killer Cell Therapy
May 21, 2024
 · 
3 min read
FDA
Indapta Therapeutics Receives U.S. FDA Fast Track Designation for Lead Clinical Drug Candidate IDP-023 for Non-Hodgkin’s Lymphoma and Myeloma
February 29, 2024
 · 
2 min read
Drug Development
Indapta Therapeutics Announces First Patients Treated with IDP-023 Allogeneic Natural Killer (NK) Cell Therapy for Cancer
January 11, 2024
 · 
2 min read
Drug Development
Indapta Therapeutics Announces U.S. FDA Clearance of IND for IDP-023, an Allogeneic Natural Killer (NK) Cell Therapy for Cancer
May 17, 2023
 · 
2 min read
Business
Indapta Therapeutics Names Moya Daniels, Senior Vice President of Regulatory, Quality and Clinical Operations
January 17, 2023
 · 
2 min read
Business
Indapta Therapeutics Names Mark W. Frohlich, M.D., Chief Executive Officer and Raises Over $50 Million in Series A Financing and Commitments to Advance Development of G-NK Cell Therapy to Treat Multiple Types of Cancer
February 10, 2022
 · 
6 min read
Load More
JOBS